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ABSTRACT
The aim of the present study was to identify graft-versus-leukemia effects and the factors that affect outcome
in 201 adults with acute lymphobalstic leukemia who received myeloablative allogeneic stem cell transplanta-
tion from matched sibling or unrelated donors (1995-2004). One hundred seventy-eight (88.6%) of these
patients had high-risk criteria, and 151 (75.1%) patients were transplanted in first complete remission (CR). All
patients received unmodified stem cell grafts (185 bone marrow and 16 peripheral blood) following total- body
irradiation-containing myeloablative preparations. Graft-versus-host disease (GVHD) prophylaxis was uni-
formly attempted by administering calcineurin inhibitor plus methotrexate. After a median follow-up of 63
months (range: 25 to 139 months) for surviving transplants, disease-free survival at 5 years was 47.8% for
all patients and 60.3% for patients in the first CR. No difference in transplantation outcome was observed
between sibling and unrelated transplants in the first CR. The most powerful predictive factor affecting
transplantation outcome was disease status at transplantation (the first CR versus beyond the first CR, P <
.001). Chronic GVHD (cGVHD), especially limited type, was also found to have a significant antileukemic
effect. Interestingly, the influence of cGVHD on relapse risk was prominent in patients with chromosomal
translocations or normal cytogenetics.
© 2007 American Society for Blood and Marrow Transplantation
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Advances in the chemotherapeutic treatment of
dult acute lymphoblastic leukemia (ALL) have re-
ulted in complete remission (CR) rates of 78% to
3%, but only 35% of these patients achieve long-
erm disease-free survival (DFS) [1-6]. Because the
igh incidence of relapse is a main cause of treatment
ailure in adults with ALL, optimal postremission therapy in particular, the efﬁcacy of allogeneic stem
ell transplantation (SCT) is a critical issue. However,
he role of allogeneic SCT in adults with ALL remains
nclear because interpretation of transplantation out-
ome is complicated by the criteria used to select
atients for transplantation and by the relatively small
umber of patients studied. Even so, allogeneic SCT
learly beneﬁts certain high-risk patients, such as
hose with Philadelphia chromosome (Ph)-positive
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S. Lee et al.1084LL or those that show a poor initial response to
hemotherapy [3,5-9]. Conversely, the role of alloge-
eic SCT for standard-risk patients remains unknown.
Whether SCT from an unrelated donor is a treat-
ent option of equal value in cases lacking a compat-
ble related donor also remains controversial. How-
ver, recent studies suggest that among adults with
LL, transplantation from a human leukocyte antigen
HLA)-matched unrelated donor or from cord blood
ould yield results similar to those achieved by
atched related donor transplantation [9-13]. Al-
hough unrelated donor transplants are generally as-
ociated with more transplant-related complications
han matched sibling transplants, a compensatory de-
rease in relapse rates from a strong graft-versus-
eukemia (GVL) effect has narrowed the gap between
he 2 approaches.
During the last 10 years, several factors could
ccount for the observed improved outcomes of allo-
eneic SCT. These include the development of sup-
ortive care facilities, the improvement of HLA typ-
ng methods, increased availability of HLA-matched
nrelated donors, and the incorporation of newly de-
eloped targeted agents (eg, imatinib) into conven-
ional treatment regimens [14-17]. Considering these
rogresses in the therapy of adult ALL, a detailed
nalysis is needed to clarify the role of allogeneic
CT. The aim of the present study was to evaluate
isk factors affecting clinical outcome and the GVL
ffect in 201 consecutive adults with ALL who were
reated with myeloablative allogeneic SCT from a
atched sibling or an unrelated donor at the Catholic
ematopoietic Stem Cell Transplantation Center be-
ween 1995 and 2004.
ATERIALS AND METHODS
atients
At our center, it is the treatment policy to offer
yeloablative or reduced-intensity allogeneic SCT to
ny adult patients (aged 15 years or older) with ALL if
n HLA-matched related donor is available. In addi-
ion, transplants from a suitably matched unrelated
onor are offered to patients with high-risk ALL, such
s Ph-positive ALL. Between 1995 and 2004, a total of
18 patients were transplanted from a matched sibling
r unrelated donor. To better evaluate the GVL effect
nd risk factors affecting transplantation outcome, 17
atients who received reduced-intensity transplanta-
ion were excluded. The analyzed study population
as composed of 201 consecutive adults with ALL
ho received myeloablative allogeneic SCT from a
atched sibling (n  152; 75.6%) or unrelated (n 
9; 24.4%) donor. Main presenting clinical and bio-
ogic features at the time of diagnosis are summarized
n Table 1. Median patient age was 30 years (range: w5-52 years). One hundred seventy-eight patients
88.6%; 129 of 152 sibling transplants, 49 of 49 un-
elated transplants) had at least 1 high-risk factor,
ncluding (1) Ph (n  67; 52 sibling transplants, 15
nrelated transplants) or t(4;11) (n  6; 5 sibling
ransplants, 1 unrelated transplant); (2) high present-
ng leukocyte counts (30  109/L for B-precursor
LL, 100  109/L for T-precursor ALL) (n  110;
7 sibling transplants, 33 unrelated transplants); or (3)
R requiring more than 28 days of induction therapy
n  66; 44 sibling transplants, 22 unrelated trans-
lants).
As shown in Table 2, 151 patients (75.1%) were
ransplanted in the ﬁrst CR; 20 (10.0%) in the second
R; and 30 (14.9%) were resistant to chemotherapy
efore transplantation. HLA compatibility was deter-
ined by either serotyping or high-resolution geno-
yping for HLA-A, -B, -C, and -DRB1, depending on
he technology available at the time of transplantation.
efore 2000, donor selection was based on HLA se-
otyping performed for class I (HLA-A, -B, and -C)
nd high-resolution genotyping (PCR-sequence-spe-
iﬁc primer [SSP]) for class II (HLA-DRB1). Since
000, all donor-recipient pairs were typed by using
igh-resolution genotyping for both HLA class I and
I antigens. Donor and recipient pairs were considered
atched when identical at HLA-A, -B, -C, and
DRB1 loci. One hundred ninety (94.5%) patients
ere transplanted from a fully matched sibling (n 
52) or an unrelated (n  38) donor, and the remain-
ng 11 (5.5%) patients were transplanted from 1 or 2
llele mismatched unrelated donors. The stem cell
ource was unmodiﬁed bone marrow (BM) in 185
92.0%) patients and peripheral blood in 16 (8.0%)
atients. All patients and donors provided written in-
ormed consent, and the treatment protocol was ap-
roved by the institutional review board of The Cath-
lic University of Korea.
reatment before SCT
Before 2000, induction therapy was started with
darubicin (12 mg/m2, days 1 to 3), vincristine (1.4
g/m2, days 1, 8, and 15), prednisone (60 mg/m2, days
to 28), and L-asparaginase (6000 IU/m2, days 17 to
8), and central nervous system (CNS) prophylaxis
onsisted of cranial irradiation (2340 cGy) and intra-
hecal methotrexate (MTX; 4 times in total) [18,19].
fter 2000, the induction regimen was changed as
ollows: hyperfractionated cyclophosphamide (300
g/m2, every 12 hours, days 1 to 3), vincristine (1.4
g/m2, days 4 and 11), idarubicin (12 mg/m2, days 4
nd 11), and dexamethasone (40 mg, days 1 to 4 and
ays 11 to 14) [16]. CNS prophylaxis was also changed
o intrathecally administered triple agents (MTX, cyt-
rabine, and methylprednisolone, 6 times in total)
ithout cranial irradiation. After induction, patients in
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Outcome of Allogeneic SCT for Adult ALL 1085R received a high-dose cytarabine-containing consoli-
ation treatment course, which depended on the time of
ransplantation. Patients with resistant or relapsed leu-
emia received salvage chemotherapy, namely, cytara-
ine (2 g/m2, every 12 hours, days 1 to 4), mitoxantrone
12 mg/m2, days 1 to 4), and etoposide (100 mg/m2, days
to 7). In addition, after 2000, most patients with Ph-
ositive ALL received imatinib interim therapy before
CT [16].
reparative Regimen and Graft-versus-Host
isease (GVHD) Prophylaxis
All patients received a myeloablative preparative
egimen, which for patients in the ﬁrst CR consisted
f total-body irradiation (TBI; 1320 cGy) and cyclo-
hosphamide (120 mg/kg), whereas patients with a more
dvanced pretransplantation disease status received TBI
1200 cGy), cytarabine (12 g/m2), and melphalan (140
g/m2). Antithymocyte globulin (ATG; 2.5 mg/kg;
angStat, Lyon, France) was administered to 11 pa-
ients who received allele mismatched unrelated
rafts. GVHD prophylaxis was attempted by admin-
stering calcineurin inhibitor (cyclosporine for all sib-
able 1. Clinical and Biologic Characteristics of 201 Patients at Diagn
Characteristics Sibling
edian age, years (range) 31 (
ge group, years
<35 (%) 91 (
>35 (%) 61 (
ecipient sex
Male (%) 78 (
Female (%) 74 (
iagnosis
B-lineage (%) 127 (
T-lineage (%) 22 (
Bi-lineage (B  T) (%) 3 (
edian WBC count, 109/L (range) 31.6 (
igh WBC count (%)* 77 (
ytogenetics
Ph (%) 52 (
t (4;11) (%) 5 (
t (1;19) (%) 5 (
Deletion (6q or 9p) (%) 9 (
Hypodiploid (%) 3 (
Hyperdiploid (%) 5 (
Normal diploid (%) 57 (
Miscellaneous (%) 13 (
Unknown (%) 3 (
M involvement (%) 58 (
elayed time to first CR, event/evaluable no. (%)† 44/145 (
isk group
Standard risk (%) 23 (
High risk (%) 129 (
BC indicates white blood cell; Ph, Philadelphia chromosome; EM
Presenting WBC counts 30  109/L for B-precursor ALL and
Time to ﬁrst CR 28 days from the start of induction chemotheing transplants and tacrolimus for all unrelated trans- tlants) plus MTX (10 mg/m2 on days 1, 3, 6, and 11).
alcineurin inhibitors were administered intrave-
ously (cyclosporine 3 mg/kg/day and tacrolimus 0.03
g/kg/day) as a continuous infusion from day 1.
ubsequently, when patients were able to tolerate oral
dministration, they received calcineurin inhibitors
rally (cyclosporine 6 mg/kg/day and tacrolimus 0.12
g/kg/day) until day 90. The dose of calcineurin
nhibitors was then gradually tapered and discontin-
ed 6 months after SCT. If residual leukemia was
etected in the absence of acute GVHD (aGVHD)
uring the follow-up period after SCT, calcineurin
nhibitors were rapidly discontinued. aGVHD was
reated with high-dose steroids, and extensive chronic
VHD (cGVHD) was treated with calcineurin inhib-
tors and steroids.
efinitions
Leukocyte engraftment was deﬁned to have oc-
urred on the ﬁrst of 3 consecutive days during which
he absolute neutrophil count was 0.5  109/L.
latelet engraftment was deﬁned to have occurred on
Number
2) P Unrelated (n  49) Total (n  201)
.003 22 (15-48) 30 (15-52)
.012
39 (79.6) 130 (64.7)
10 (20.4) 71 (35.3)
.050
33 (67.3) 111 (55.2)
16 (32.7) 90 (44.8)
.118
39 (79.6) 166 (82.6)
6 (12.2) 28 (13.9)
4 (8.2) 7 (3.5)
.0) .207 37.6 (1.2-481.0) 33.0 (0.5-653.0)
.041 33 (67.3) 110 (54.7)
.700
15 (30.6) 67 (33.3)
1 (2.1) 6 (3.0)
0 (0) 5 (2.5)
3 (6.1) 12 (6.0)
2 (4.1) 5 (2.5)
0 (0) 5 (2.5)
20 (40.8) 77 (38.3)
6 (12.2) 19 (9.4)
2 (4.1) 5 (2.5)
.037 27 (55.1) 85 (42.3)
.039 22/47 (46.8) 66/192 (34.4)
.004
0 (0) 23 (11.4)
49 (100) 178 (88.6)
amedullary; CR, complete remission.
109/L for T-precursor ALL.osis
(n  15
15-52)
59.9)
40.1)
51.3)
48.7)
83.6)
14.4)
2.0)
0.5-653
50.7)
34.2)
3.3)
3.3)
5.9)
2.0)
3.3)
37.5)
8.5)
2.0)
38.2)
30.3)
15.1)
84.9)
, extr
100 he ﬁrst of 7 consecutive days with a platelet count of

w
s
t
e
l
B
w
a
d
B
w
s
t
B
S
w
t
v
t
t
k
ﬁ
D
s
l
c
w
D
c
p
p
c
d
F
a
l
S
T
D
H
S
B
G
P
M
M
M
M
M
A
C
M
H
* ranspla
S. Lee et al.108620  109/L without transfusion support. aGVHD
as diagnosed and graded using previously published
tandard criteria [20]. cGVHD was assessed in pa-
ients that survived more than 100 days with sustained
ngraftment after transplantation and was deﬁned as
imited or extensive [21].
CR was deﬁned as the reconstitution of normal
M cellularity with 5% leukemic blasts, together
ith an absolute neutrophil count of 1.5  109/L
nd a platelet count of 100  109/L. Relapse was
eﬁned by the reappearance of 5% leukemic cells in
M aspirates or extramedullary leukemia in patients
ith previously documented CR. Patients were con-
idered refractory if peripheral blood blasts or ex-
ramedullary disease had not been eliminated, or if
M blasts had not been reduced to 5%, or both.
tatistical Analysis
Proportions of patients with a given characteristic
ere compared using the chi square or Fisher’s exact
able 2. Clinical and Biologic Characteristics of 201 Patients at Transp
Characteristics Sibli
isease status at transplantation
First CR (%) 1
Second CR (%)
Relapse or refractory (%)
LA incompatibility
Matched (%) 1
Mismatched (%)
ex incompatibility
Matched (%)
Male to female (%)
Female to male (%)
lood type incompatibility
Matched (%)
Minor (%)
Major or bidirectional (%)
raft type
Bone marrow (%) 1
Peripheral blood (%)
eriod of transplantation
Before 2000 (%)
After 2000 (%) 1
edian time to transplantation, days (range)* 1
edian CD34 cells, 106/kg (range) 3
edian CD3 cells, 107/kg (range) 4
edian time to ANC >0.5  109/L, days (range)
edian time to platelet >20  109/L, days (range)
cute GVHD, event/evaluable no. (%) 60/1
Grade II (%)
Grade III/IV (%) 11
hronic GVHD, event/evaluable no. (%) 64/1
Limited (%)
Extensive (%)
edian follow-up after transplantation, months (range)
LA indicates human leukocyte antigen; ANC, absolute neutroph
Interval from the start of induction chemotherapy to the date of tests. Differences between the means of continuous sariables were checked using the Mann-Whitney U-
est. Survival duration was calculated from the date of
ransplantation until death or the date when last
nown alive. Nonrelapse mortality (NRM) was de-
ned as death occurring in relapse-free patients.
eath resulting from any cause after relapse was con-
idered to have been caused by relapse. When calcu-
ating DFS, both relapses and deaths in CR were
ounted as adverse events. The cumulative relapse rate
as calculated using the same type of analysis used for
FS, excepting those who died in CR, who were
ensored at the time of death. Survival curves were
lotted using the Kaplan-Meier method and com-
ared by the log-rank test. The prognostic signiﬁ-
ances of presenting and transplant covariables were
etermined using the Cox proportional hazard model.
actors were considered signiﬁcant if they had an
ssociated P-value of .05 as determined by the like-
ihood ratio test, using 2-tailed signiﬁcance testing.
tatistical analyses were performed using SPSS 13.0
n
Number
152) P Unrelated (n  49) Total (n  201)
.007
.3) 32 (65.3) 151 (75.1)
.2) 3 (6.1) 20 (10.0)
.5) 14 (28.6) 30 (14.9)
<.001
0) 38 (77.6) 190 (94.5)
11 (22.4) 11 (5.5)
.930
.0) 27 (55.1) 106 (52.7)
.3) 12 (24.5) 52 (25.9)
.7) 10 (20.4) 43 (21.4)
.005
.2) 17 (34.7) 110 (54.7)
.8) 14 (28.6) 38 (18.9)
.0) 18 (36.7) 53 (26.4)
.078
.1) 48 (98.0) 185 (92.0)
) 1 (2.0) 16 (8.0)
.680
.6) 13 (26.5) 58 (28.9)
.4) 36 (73.5) 143 (71.1)
-360) <.001 191 (127-294) 150 (56-360)
-28.7) .701 3.4 (1.3-13.0) 3.3 (0.9-28.7)
-34.8) .417 4.1 (1.8-8.0) 4.3 (0.1-34.8)
-27) .690 15 (11-27) 15 (10-27)
-72) .025 25 (14-44) 21 (10-72)
.8) .469 22/47 (46.8) 82/194 (42.3)
.0) 14 (29.8) 61 (31.5)
) 6/2 (17.0) 17/4 (10.8)
.4) .314 21/35 (60.0) 85/162 (52.5)
.7) 6 (17.1) 31 (19.2)
.7) 15 (42.9) 54 (33.3)
-139) .021 47 (26-126) 63 (25-139)
ts; CR, complete remission; GVHD, graft-versus-host disease.
ntation.lantatio
ng (n 
19 (78
17 (11
16 (10
52 (10
0 (0)
79 (52
40 (26
33 (21
93 (61
24 (15
35 (23
37 (90
15 (9.9
45 (29
07 (70
39 (56
.3 (0.9
.3 (0.1
15 (10
21 (10
47 (40
47 (32
/2 (8.8
27 (50
25 (19
39 (30
67 (25
il counoftware (SPSS, Chicago, IL).
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Outcome of Allogeneic SCT for Adult ALL 1087ESULTS
ngraftment and GVHD
One hundred ninety-four patients survived be-
ond the ﬁrst 28 days after transplantation, and all
chieved successful leukocyte and platelet engraftment
t a median of 15 days (range: 10-27 days) and 21 days
range: 10-72 days) after transplantation, respectively.
even patients died prior to engraftment. Eighty-two
42.3%) of the 194 evaluable patients developed
rades II through IV aGVHD (61 grade II, 17 grade
II, 4 grade IV). Of the 162 patients who survived at
east 100 days with sustained engraftment after SCT,
5 (52.5%) developed cGVHD (31 limited, 54 exten-
ive). No signiﬁcant difference in the incidence of
GVHD and cGVHD was observed between the 2
onor types (Table 2).
verall Transplantation Outcome: Sibling
ransplants versus Unrelated Transplants
After a median follow-up of 63 months (range: 25
o 139 months) for surviving transplants, 101 (50.2%;
0 sibling, 21 unrelated) remained alive, and 96 (75
ibling, 21 unrelated) of the 101 remained in continuous
R. At the time of analysis (February 28, 2007), 100
49.8%) of the 201 patients had died. Forty-three
43.0%) of these 100 died of causes other than leukemic
elapse, and the remaining 57 patients (57.0%) died of
rogressive leukemia. Sixty-two patients (30.8%) re-
apsed at a median of 9 months (range: 1-71 months)
fter transplantation. The 5-year relapse, NRM, DFS,
nd overall survival (OS) rates for all 201 patients were
6.6%  3.8%, 23.5%  3.2%, 47.8%  3.6%, and
9.8%  3.6%, respectively (Table 3).
Comparing transplantation outcome for sibling and
nrelated transplants, a tendency in favor of patients that
eceived a transplantation from a matched sibling donor
as observed in terms of NRM (21.4%  3.6% versus
9.3%  6.6%, P  .086) and OS (52.4%  4.1%
ersus 42.1%  7.2%, P  .067). However, when con-
idering disease status at time of transplantation, partic-
able 3. Outcome in the Sibling Transplants versus Unrelated Transpl
Variables Relapse
verall (n  201) 36.6  3.8
Sibling (n  152) 36.1  4.3
P .628
Unrelated (n  49) 38.2  8.1
irst CR (n  151) 24.2  3.8
Sibling (n  119) 25.2  4.3
P .651
Unrelated (n  32) 19.9  8.0
First CR (n  50) 84.0  6.5
Sibling (n  33) 82.8  7.7
P .684
Unrelated (n  17) 86.6  12.1RM indicates nonrelapse mortality; CR, complete remission; DFS, disealarly in those transplanted in the ﬁrst CR, no difference
as found between sibling (n 119) and unrelated (n
2) transplants in terms of relapse (25.2%  4.3% ver-
us 19.9%  8.0%), NRM (19.1%  3.8% versus
1.9%  7.3%), DFS (59.9%  4.6% versus 62.5% 
.6%), andOS (63.9% 4.5% versus 61.5% 8.8%) at
years after SCT (Figure 1). Similarly, in patients trans-
lanted in beyond the ﬁrst CR, no difference was found
ccording to donor type (33 sibling transplants versus 17
nrelated transplants) in terms of relapse (82.8% 
.7% versus 86.6%  12.1%), NRM (25.4%  7.8%
ersus 45.1%  13.0%), DFS (12.1%  5.7% versus
.9%  5.7%), and OS (11.4%  5.7% versus 5.9% 
.7%) rates (Table 3).
actors Affecting Transplantation Outcome
In terms of potential risk factors of relapse the
ollowing were identiﬁed by univariate analysis:
resenting leukocyte counts, risk group, disease
tatus at the time of transplantation, period of
ransplantation, blood type incompatibility, and
GVHD. NRM was adversely inﬂuenced by pa-
ients aged 35 years or older, high leukocyte count,
xtramedullary involvement, advanced disease sta-
us at the time of transplantation, unrelated trans-
lant, and the presence of aGVHD. The potential
ariables predicting poorer DFS and OS were pa-
ients aged 35 years or older, male recipient, high
eukocyte count, extramedullary involvement, de-
ayed time to the ﬁrst CR, high-risk group, ad-
anced disease status at the time of transplantation,
nrelated transplant, transplantation before 2000,
atched blood typing, and cGVHD (limited or
xtensive type) (Table 4).
Further multivariate analysis showed that the most
owerful predictive factor affecting relapse, DFS, and
S was disease status at the time of transplantation (P
001). The 5-year relapse, DFS, and OS rates were,
espectively, 24.2% 3.8%, 60.3% 4.0%, and 63.3%
4.0%, respectively, for the 151 patients that received
at 5 Years after Transplantation
RM DFS OS
 3.2 47.8  3.6 49.8  3.6
 3.6 49.5  4.1 52.4  4.1
.086 .134 .067
 6.6 42.9  7.1 42.1  7.2
 3.4 60.3  4.0 63.3  4.0
 3.8 59.9  4.6 63.9  4.5
.455 .858 .600
 7.3 62.5  8.6 61.5  8.8
 6.9 10.0  4.2 9.6  4.3
 7.8 12.1  5.7 11.4  5.7
.251 .269 .200
 13.0 5.9  5.7 5.9  5.7ants
%
N
23.5
21.4
29.3
19.8
19.1
21.9
31.9
25.4
45.1se-free survival; OS, overall survival.
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S. Lee et al.1088ransplantation during the ﬁrst CR, and 84.0% 6.5%,
0.0%  4.2%, and 9.6%  4.3%, respectively, for the
emaining 50 patients with a more advanced disease
tatus at transplantation. Eighty-ﬁve (52.5%) of the 162
valuable patients had cGVHD (31 limited, 54 exten-
ive). The presence of cGVHD, especially the limited
ype, was also found to be signiﬁcantly associated with
ower relapse (P  .001) and better DFS (P  .002) and
S (P .006). The 5-year relapse rate for patients with
imited (16.5%  6.8%) or extensive (17.0%  5.5%)
GVHD was signiﬁcantly lower than that for patients
ithout cGVHD (48.5%  5.9%). No difference in
elapse risk was observed between patients with limited
GVHD and those with extensive cGVHD. Patients
ith limited cGVHD had better DFS (83.5%  6.8%
ersus 60.2%  6.8% versus 48.9%  5.8%) and OS
82.7%  7.1% versus 60.2%  6.8% versus 53.5% 
.8%) than those with extensive cGVHD or those with-
ut cGVHD (Figure 2). In addition, patients who re-
eiving transplantation after 2000 showed an improve-
ent in relapse (32.4% 4.4% versus 47.0% 7.2%,
 .015), DFS (50.9%  4.3% versus 37.9% 
.4%, P  .016), and OS (53.0%  4.3% versus
9.1%  6.5%, P  .032). The presence of aGVHD
ad a detrimental effect on NRM (Table 5).
ntileukemic Activity of cGVHD According to
ytogenetic Patterns
One hundred sixty-one of the 162 evaluable pa-
ients for cGVHD had a successful cytogenetic data at
he time of diagnosis (74 translocations, 63 normal
igure 1. Probabilities of A, relapse, B, nonrelapse mortality, C, d
rst CR from matched sibling or unrelated donors. Solid line indiciploid, 24 deletion or numeric abnormalities). A sep- frate analysis of the antileukemic effect of cGVHD
ccording to presenting cytogenetic patterns showed
hat the negative inﬂuence of cGVHD on relapse risk
as stronger in 74 evaluable patients with chromo-
omal translocations at the time of diagnosis. Of these,
4 patients (73.0%) were Ph-positive ALL, and 29 of
hese received imatinib interim therapy before trans-
lantation. The remaining 20 patients had t(4;11) (n
), t(1;19) (n  4), and other translocations (n  11).
he 5-year relapse rates were 18.3%  6.8% for the
6 patients with cGVHD and 60.3%  8.2% for the
emaining 38 patients without cGVHD, respectively
P  .001). The antileukemic activity of cGVHD was
lso shown in 63 patients with normal diploid. The
-year relapse rates were 15.1%  6.3% for the 40
atients with cGVHD and 39.7%  10.3% for the
emaining 23 patients without cGVHD, respectively
P  .013). On the other hand, the inﬂuence of
GVHD on relapse risk was absent in patients having
eletion or numeric abnormalities (n  24; 22.2% 
3.9% versus 27.3%  11.7%, P  .782) (Figure 3).
ISCUSSION
To our knowledge, this is the largest published re-
ort issued by a single center on adults with ALL (201
atients; 88.6% of these patients had high-risk factors)
reated by matched sibling or unrelated TBI-containing
yeloablative SCT. In this study, the most powerful
actor inﬂuencing transplantation outcome was disease
tatus at the time of transplantation. After a median
ree survival, and D, overall survival in patients transplanted in the
ling transplants; dotted line, unrelated transplants.isease-follow-up of 63 months for surviving transplants, the
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Outcome of Allogeneic SCT for Adult ALL 1089-year DFS rate (47.8% for all transplants) was 60.3%
or 151 transplants in the ﬁrst CR and 10.0% for 50
ransplants with a more advanced disease status at the
ime of transplantation. Furthermore, although all unre-
ated transplants had high-risk factors, we did not ob-
erve any signiﬁcant differences in DFS between patients
hat received a graft from a matched sibling or an unre-
ated donor in the ﬁrst CR (59.9% versus 62.5%).
Several potential factors could account for our
able 4. Univariate Analyses of Potential Variables affecting Transplan
Variables n Relapse P
ge, years .792
<35 130 35.9  4.6 19.
>35 71 38.1  6.7 31.
ex .321
Male 111 38.7  5.2 25.
Female 90 34.2  5.5 21.
iagnosis .511
B-lineage 166 35.6  4.1 22.
Others 35 41.3  9.2 27.
BC count .189
Low 91 33.2  5.4 19.
High 110 39.8  5.3 27.
ytogenetics .213
Ph/t (4;11) 73 42.1  6.3 22.
Others 128 33.5  4.7 23.
M involvement .343
Positive 85 40.1  6.1 28.
Negative 116 34.3  4.8 19.
ime to first CR, days .221
<28 126 30.9  4.5 22.
>28 66 41.6  6.8 24.
isk group .146
Standard risk 23 25.4  9.9 15.
High risk 178 38.3  4.1 24.
isease status at SCT <.001
First CR 151 24.2  3.8 19.
>First CR 50 84.0  6.5 31.
onor type .628
Sibling 152 36.1  4.3 21.
Unrelated 49 38.2  8.1 29.
eriod of SCT .021
Before 2000 58 47.0  7.2 22.
After 2000 143 32.4  4.4 23.
ex incompatibility .987
Matched 106 36.3  5.2 23.
Mismatched 95 37.2  5.6 24.
BO incompatibility .060
Matched 110 42.1  5.3 25.
Mismatched 91 30.3  5.3 21.
cute GVHD .288
Positive 82 33.7  6.1 31.
Negative 112 38.3  4.9 13.
hronic GVHD <.001
Limited 31 16.5  6.8 .925*
Extensive 54 17.0  5.5 27.
Negative 77 48.5  5.9 4.
CT indicates stem cell transplantation; GVHD, graft-versus-host
cell; NRM, nonrelapse mortality; DFS, disease-free survival; O
Statistical difference between limited chronic GVHD and extensivomewhat better overall outcome for allogeneic SCT en comparison with those obtained by other large-
cale studies [10,22]. One potential factor is the rela-
ive youth of the patient population in the present
tudy, especially higher proportions of younger unre-
ated transplants (median age, 22 years). Doney et al.
22] analyzed the outcomes of 182 adult ALL patients
median age, 29.4 years; 5-year DFS rate, 21%) and
ound that patients younger than 40 years of age had
igniﬁcantly improved DFS and overall survival. Kiehl
Outcome in All Transplants
t 5 Years after Transplantation
P DFS P OS P
.066 .165 .063
51.1  4.4 53.5  4.5
41.7  5.9 43.1  5.9
.354 .161 .136
44.8  4.8 46.1  4.8
51.4  5.4 54.4  5.4
.737 .475 .433
48.9  3.9 51.0  3.9
42.4  8.4 45.1  8.5
.087 .032 .041
53.5  5.4 55.2  5.4
42.6  4.7 45.1  4.8
.805 .414 .446
43.7  5.8 44.6  5.9
50.1  4.5 53.0  4.5
.159 .101 .152
41.9  5.4 45.2  5.5
52.1  4.7 53.2  4.7
.599 .196 .161
52.6  4.5 55.5  4.5
43.8  6.1 44.4  6.3
.228 .055 .039
62.2  10.8 66.7  10.4
45.9  3.8 47.7  3.8
.008 <.001 <.001
60.3  4.0 63.3  4.0
10.0  4.2 9.6  4.3
.086 .134 .067
49.5  4.1 52.4  4.1
42.9  7.1 42.1  7.2
.963 .062 .075
37.9  6.4 39.1  6.5
50.9  4.3 53.0  4.3
.783 .897 .592
48.1  5.0 51.4  5.0
47.2  5.1 48.0  5.2
.490 .052 .064
45.2  4.7 44.9  4.8
54.0  5.3 55.4  5.4
.003 .338 .228
44.7  5.5 47.0  5.6
53.1  4.8 55.0  4.8
.893 .001 .003
.003* 83.5  6.8 .045 82.7  7.1 .021*
60.2  6.8 60.2  6.8
48.9  5.8 53.5  5.8
EM, extramedullary; CR, complete remission; WBC, white blood
all survival.
nic GVHD.tation
% a
NRM
3  3.7
6  6.0
5  4.4
1  4.7
9  3.5
6  8.8
1  4.7
5  4.5
9  5.3
7  4.0
7  5.4
6  3.9
8  4.0
4  5.6
7  8.7
4  3.4
8  3.4
9  6.9
4  3.6
3  6.6
9  5.9
8  3.9
3  4.5
0  4.6
2  4.5
7  4.7
5  5.4
3  3.6
0
0  6.6
5  2.5
disease;
S, overt al. [10] also analyzed the outcomes of 221 adult
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S. Lee et al.1090LL patients (median age, 32 years for related trans-
lants and 29 years for unrelated transplants; 5-year
FS rate, 28%) and observed that patients aged 17-26
ears showed a better DFS in comparison with pa-
ients aged 27 years or older. Therefore, the relevance
f age factor with regard to transplantation outcome
hould be continuously considered. Additional poten-
ial factors were relatively higher proportions of
atched sibling transplants (n  152; 75.6%), higher
umber of transplants performed after 2000 (n  143;
1.1%), the positive role of imatinib interim therapy
n transplantation outcome for Ph-positive ALL [16],
elatively more uniform strategy for TBI-containing
igure 2. Inﬂuence of disease status at time of transplantation (A,
right column) in all transplants. Solid line indicates transplants in th
he presence of extensive cGVHD; dotted line, transplants in beyo
able 5. Multivariate Analyses of Independent Variables affecting Tran
Variables
Relapse
RR (95% CI) P RR (95%
isease status at SCT
First CR 1 —
>First CR 10.1 (5.4-19.2) <.001 —
hronic GVHD
Limited 1 —
Extensive 1.1 (0.4-3.3) — —
Negative 5.3 (2.2-12.9) <.001 —
eriod of SCT
After 2000 1 —
Before 2000 2.1 (1.2-4.0) .015 —
cute GVHD
Negative — — 1
Positive — — 3.3 (1.2-
R indicates relative risk; CI, conﬁdence interval; NRM, nonrelapse
transplantation; GVHD, graft-versus-host disease; CR, complete remiyeloablative preparation and GVHD prophylaxis,
hoice of BM as a main graft source (n  185;
2.0%), and center effects, that is, a single trans-
lantation center setting versus a multicenter set-
ing.
Some limitations of the present study should be
onsidered. The ﬁrst is the different strategy for pre-
ransplantation treatment and HLA typing according
o period of transplantation (before 2000 versus after
000). In addition, regimens for preparation and
VHD prophylaxis were different according to pre-
ransplantation disease status (TBI  cyclophospha-
ide for transplants in the ﬁrst CR versus TBI 
cGVHD (C, D) on relapse (left column) and disease-free survival
CR and the presence of limited cGVHD, respectively; dashed line,
ﬁrst CR and the absence of cGVHD, respectively.
tion Outcome in All Transplants
DFS OS
P RR (95% CI) P RR (95% CI) P
— 1 1
— 6.5 (3.7-11.6) <.001 6.7 (3.7-12.0) <.001
— 1 1
— 3.3 (1.1-9.6) .029 4.7 (1.4-15.7) .013
— 5.8 (2.0-16.4) .002 6.7 (2.1-22.2) .006
— 1 1
— 1.9 (1.1-3.2) .016 1.8 (1.1-3.2) .032
— — — —
.026 — — — —
lity; DFS, disease-free survival; OS, overall survival; SCT, stem cellB) and
e ﬁrstsplanta
NRM
CI)
9.6)
morta
ssion.
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Outcome of Allogeneic SCT for Adult ALL 1091ytarabine  melphalan for transplants in beyond the
rst CR) and donor type (cyclosporine for sibling
ransplants versus tacrolimus for unrelated trans-
lants), respectively. Here, we analyzed the inﬂuence
f these limitations on transplantation outcome by
sing categorized variables as follows: period of trans-
lantation, disease status at transplantation, and donor
ype. Further large studies with a homogenous patient
opulation are needed to validate the results of this
tudy.
Nevertheless, our ﬁndings are in keeping with
ther studies that disease status at the time of trans-
lantation, rather than donor type, is the most impor-
ant determinant of outcome after transplantation.
oney et al. [22] analyzed the outcomes of adult ALL
atients (most patients had high-risk factors) treated
ith allogeneic SCT from matched (88 related and 33
nrelated) or mismatched (26 related and 35 unre-
ated) donors between 1990 and 1997. They found
hat patients who underwent transplantation in the
rst CR had signiﬁcantly (P  .001) better 5-year
FS (43%) than those who underwent transplantation
n second or later CRs (24%) or in relapse (9%). Kiehl
t al. [10] compared the outcomes of adult ALL pa-
ients (64% of these patients had high-risk factors)
reated by matched related (n  103) or matched
nrelated (n  118) SCT at 9 European centers from
990 to 2002. They observed a DFS advantage for
atients that received transplantation during the ﬁrst
R versus those who received transplantation in a
ore advanced disease status. In addition, in this re-
igure 3. Antileukemic activity of cGVHD according to cytogeneti
nd C, deletion or numerical abnormality group. Solid line indicatort, although signiﬁcantly more patients received re- pated SCT in the ﬁrst CR (60% versus 27%, P 
001), no signiﬁcant difference in 5-year DFS (42%
ersus 45%) was observed between related and unre-
ated donor SCT in the ﬁrst CR. In conjunction with
ata from a recent evidence-based review [23] and
eta-analysis [24], these results indicate that alloge-
eic SCT should be recommended in high-risk ALL
atients during the ﬁrst CR, if possible.
On the other hand, the role of allogeneic SCT in
tandard-risk ALL patients in the ﬁrst CR remains
ncertain. Interestingly, the United KingdomMedical
esearch Council ALL XII/European Cooperative
ncology Group E2993 trial [25] recently demon-
trated a beneﬁt for allogeneic SCT from matched
ibling donors in standard-risk patients in the ﬁrst CR.
heir ﬁnal 5-year results show a signiﬁcantly re-
uced relapse rate (25% versus 48%, P  .05) and
etter event-free survival (EPS; 59% versus 48%, P 
05) and OS (63% versus 51%, P  .05) rates in
tandard-risk patients assigned to allogeneic SCT
n  218) versus those assigned to autologous SCT or
hemotherapy (n  286). This raises an important
uestion if no matched sibling donor is available, as to
hether the recommendation of unrelated SCT for
tandard-risk ALL patients in the ﬁrst CR is reason-
ble or not. Kiehl et al. [10] reported that transplant-
elated mortality is not signiﬁcantly different for
atched related donor transplants and matched unre-
ated donor transplants (39% versus 31%) in the ﬁrst
R. Recently, the French Society of Bone Marrow
ransplantation and Cell Therapy [26] performed a
ns. A, Chromosomal translocation group, B, normal diploid group,
resence of cGVHD; dotted line, the absence of cGVHD.c patterrospective study in which the outcomes of 236 pa-
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S. Lee et al.1092ients with standard-risk hematologic malignancy (175
cute leukemia, 43 chronic myelogenous leukemia
CML), and 18 myelodysplastic syndrome) treated
ith 10/10 HLA-allelic-matched unrelated SCT (n 
5) were compared with matched sibling SCT (n 
81). They demonstrated that transplantation from
LA-allelic-matched unrelated donors led to out-
omes similar to those from matched sibling donors.
ur data also show that the probability of NRM at 5
ears is not different for sibling and unrelated trans-
lants, especially those conducted in the ﬁrst CR
19.1% versus 21.9%). Thus, given the reﬁnement of
LA typing using molecular methods and the devel-
pment of supportive care facilities, indications for
llogeneic SCT for adult ALL should be continuously
valuated in light of procedural improvements.
In the present study, the incidence of aGVHD was
2.3% (40.8% for sibling transplants, 46.8% for un-
elated transplants) and that of severe (grade III-IV)
GVHD was 10.8% (8.8% for sibling transplants,
7.0% for unrelated transplants). The incidence of
evere aGVHD is lower than that of other reports
9,22]. Conversely, Kiehl et al. [10] reported that the
ncidence of grade III-IV GVHD was 11% (7% for
elated transplants, 15% for unrelated transplants).
he Swedish Adult ALL Group [27] also reported
hat the incidence of grade III-IV GVHD was 9%.
hese conﬂicting ﬁndings are mainly from heteroge-
eities in patient population and treatment methods.
he association of ethnicity with the incidence of
VHD may also account for the relatively lower in-
idence of severe aGVHD in our patient population.
ecently, Oh et al. [28] reported that Japanese and
candinavian people had signiﬁcantly lower inci-
ences of aGVHD than American and Irish people in
he setting of HLA-identical sibling transplantation.
Although it remains unclear whether the antileu-
emic effect is mediated by the same immune cells as
VHD, a close relationship between GVHD and the
VL effect have been continuously reported in adult
LL. Regarding the role of aGVHD in ALL, data
rom the International Bone Marrow Transplant Reg-
stry [29] shows a strong aGVHD-related antileuke-
ic effect in patients with ALL. Kiehl et al. [10] also
eported a close relationship between aGVHD and
he GVL effect in patients with ALL, as DFS was
mproved in the presence of grade I to II aGVHD
ompared to those without GVHD (P  .018) or
evere (P  .001) aGVHD. On the other hand, we
reviously reported an inverse relationship between
GVHD and relapse in patients with ALL who un-
erwent transplantation in remission [18,19]. In the
resent study, we conﬁrm the antileukemic activity of
GVHD in terms of preventing leukemia recurrence.
he presence of cGVHD, especially the limited type,
as found to be signiﬁcantly associated with lower
elapse risk (P  .001), and this translated into DFS tmprovements (P  .002). In addition, no difference
as found in relapse rates according to severity of
GVHD, whereas limited cGVHD had a more signif-
cant impact on DFS and OS than extensive cGVHD.
hese conﬂicting results may result from heterogene-
ties in patient populations, preparative regimens, pro-
hylactic methods used for GVHD, and transplanta-
ion period. Nevertheless, our ﬁndings are supported
y other reports [30-34]. Ringden et al. [30] observed
hat cGVHD had an antileukemic effect in ALL pa-
ients transplanted in the ﬁrst CR. Zikos et al. [32]
nalyzed the outcomes of 170 patients with ALL
reated with allogeneic SCT between 1978 and 1996
nd found that cGVHD was negatively related to
elapse (P  .002) and positively related to survival
P  .001). Recently, Nordlander et al. [34] studied
99 patients with ALL who underwent allogeneic
CT between 1981 and 2001 and found that the most
igniﬁcant prognostic factors associated with relapse
nd DFS was the presence of cGVHD (P  .001).
One interesting ﬁnding of the present study is that
he inﬂuence of cGVHD on relapse risk was found to
e prominent in patients with translocations, which
ncluded 73.0% of patients with Ph-positive ALL. In
ddition, the antileukemic activity of cGVHD was
bserved in patients with normal diploid, whereas it
as absent in patients with deletion or numeric ab-
ormalities. Regarding the role of cGVHD in adults
ith Ph-positive ALL, Cornelissen et al. [9] con-
luded that Ph-positive ALL does illustrate the GVL
ffect, because they found signiﬁcantly fewer relapses
relative risk  .33, P  .05) and better DFS (relative
isk  .49, P  .006) in adults with Ph-positive ALL
hat underwent unrelated transplantation versus ALL
atients with other karyotypes. According to data from
he Seattle group [35], patients with cGVHD show a
igniﬁcantly lower risk of relapse (relative risk  .33,
 .038) in Ph-positive ALL. We have previously
onﬁrmed the antileukemic effect of cGVHD objec-
ively by serially monitoring minimal residual disease
MRD) levels in Ph-positive ALL [16,19]. Based on
hese results, the presence of chimeric proteins pro-
uced by chromosomal translocations may act as a
otential target for donor immune cells. On the other
and, to date, no data are available regarding the role
f cGVHD in ALL patients with normal diploid.
ecently, multiple acquired gene mutations and
hanges in gene expression with prognostic signiﬁ-
ance have been discovered in acute leukemia patients
ith normal cytogenetics [36,37]. Therefore, proteins
ncoded by submicroscopic genetic alternations might
e a potential target for donor immune cells in ALL
atients with normal cytogenetics. If this hypothesis is
eriﬁed, it is much better that patients with ALL
xperience some degree of cGVHD, especially in
hose with targeted proteins for donor immune cells,
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Outcome of Allogeneic SCT for Adult ALL 1093ecause this protects against leukemia relapse and
ranslates into a survival advantage.
Even though GVHD remains a major obstacle to
RM after allogeneic SCT, some investigators have
ocused on modulating GVHD to produce a GVL
ffect and has demonstrated that the use of low-dose
mmunosuppressant or an early discontinuation ap-
roach have a signiﬁcant impact on leukemia relapse
38-41]. Considering this relationship between the
VL effect and the modulation of GVHD prophy-
axis, it is interesting that the efﬁcacy of donor lym-
hocyte infusion (DLI) was uniformly dismal in ALL
atients that relapsed after allogeneic SCT even after
he occurrence of GVHD [42-44]. These conﬂicting
esults may result from the rapid pace of the disease
nd the delayed antileukemic effect of DLI. Another
ossible hypothesis is that the GVHD-related GVL
ffect is considerably inﬂuenced by MRD level, be-
ause DLI is usually recommended to treat leukemia
elapse when MRD levels are high. We believe that
RD-based postgrafting immunomodulation in com-
ination with targeted therapies at earliest disease
ecurrence may have a potential role in the long-term
ontrol of residual leukemia in ALL.
In summary, our data suggests that allogeneic SCT
n the ﬁrst CR enhances GVL effect in adults with ALL.
he presence of cGVHD results in lower relapse and
etter DFS, indicating a clinically important GVL effect.
urther studies aimed at developing treatment strategies
o reduce leukemic cell burden before transplantation
nd to enhance the postgrafting GVL effect are needed.
he indications for allogeneic SCT in adult ALL should
lso be continuously evaluated.
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